Oncolytics Biotech (ONCY) Receivables - Net (2009 - 2017)

Oncolytics Biotech (ONCY) has reported Receivables - Net for 9 consecutive years, with $33129.0 the latest figure, recorded in Q3 2017.

• On a quarterly basis, Receivables - Net fell 26.37% year-over-year to $33129.0 in Q3 2017; TTM through Sep 2017 was $33129.0, a 26.37% decrease from a year earlier, with the FY2016 full-year figure at $54406.0, down 84.0% from the prior year.
• Receivables - Net was $33129.0 for Q3 2017 at Oncolytics Biotech, down from $62109.0 in the prior quarter.
• Over five years, Receivables - Net peaked at $340059.0 in Q4 2015 and troughed at $31236.0 in Q2 2013.
• A 5-year average of $89538.9 and a median of $54406.0 in 2016 frame the typical range for Receivables - Net.
• The widest YoY moves for Receivables - Net: up 365.92% in 2016, down 84.0% in 2016.
• Over 5 years, Receivables - Net stood at $105853.0 in 2013, then jumped by 81.15% to $191751.0 in 2014, then soared by 77.34% to $340059.0 in 2015, then tumbled by 84.0% to $54406.0 in 2016, then tumbled by 39.11% to $33129.0 in 2017.
• The last three Receivables - Net figures came in at $33129.0 (Q3 2017), $62109.0 (Q2 2017), and $36484.0 (Q1 2017), per Business Quant data.